Ken Frazier, chairman and chief executive officer at Merck, explains the company's work on immune-oncology treatment for cancer patients, the amount of R&D money it takes to bring a new medicine to market, drug pricing and health care costs, and the battle against Alzheimer's disease, and the need for acquisitions. He speaks with Bloomberg's David Westin on "Bloomberg ‹GO›." (Source: Bloomberg)
